Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects

Antimicrobial Agents and Chemotherapy · Published 2026-06-15 · DOI 10.1128/aac.00524-26

Free full text

Authors (10)

Keith Rodvold, Mark Gotfried, Aramayis Kocharyan, Grigor Mamikonyan, Qifeng Shi, Hui Zhao, Ting Hu, Allan Xu, Meijie Le, Jianguo Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Rodvold, K., Gotfried, M., Kocharyan, A., et al. (2026). Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00524-26

Related articles

• Novel Therapeutic Approaches and Alternatives to Antibiotic Therapy for Drug-Resistant Intra-Abdominal Infections · Antibiotics · 2026 · Cites or is cited by this article
• In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli · Antibiotics · 2026 · Cites or is cited by this article
• PER-14, a β-lactamase variant with reduced sensitivity to avibactam and relebactam · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• An Achilles' heel for methicillin-resistant Staphylococcus aureus ? Re-evaluating β-lactam susceptibility of MRSA · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Development of domain-specific probes of Plasmodium falciparum heat shock protein 70-1 · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Primaquine-derived 5,6-orthoquinone concentrations in urine associated with CYP2D6 genotype-predicted phenotype and blood methemoglobin levels · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Selective digestive decontamination and antimicrobial resistance: defining thresholds before global implementation · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Recalculation of inhibitor concentration fold-changes for CMY-219: comments on a recent article about CMY-219 conferring resistance to ceftazidime-avibactam · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• NagX, a periplasmic β- N -acetylglucosaminidase, contributes to NagZ-independent β-lactamase expression in Stenotrophomonas maltophilia · Antimicrobial Agents and Chemotherapy · 2026 · Same journal